RT Journal Article
T1 Pharmacological Properties of Bergapten: Mechanistic and Therapeutic Aspects
A1 Quetglas Llabrés, Maria Magdalena
A1 Quispe, Cristina
A1 Herrera-Bravo, Jesús
A1 Catarino, Marcelo D
A1 Pereira, Olívia R
A1 Cardoso, Susana M.
A1 Dua, Kamal
A1 Chellappan, Dinesh Kumar
A1 Pabreja, Kavita
A1 Satija, Saurabh
A1 Mehta, Meenu
A1 Sureda, Antoni
A1 Martorell, Miquel
A1 Satmbekova, Dinara
A1 Yeskaliyeva, Balakyz
A1 Rasool, Naeem
A1 Butnariu, Monica
A1 Bagiu, Iulia Cristina
A1 Bagiu, Radu Vasile
A1 Calina, Daniela
A1 Cho, William C.
AB Bergapten (BP) or 5-methoxypsoralen (5-MOP) is a furocoumarin compound mainly found in bergamot essential oil but also in other citrus essential oils and grapefruit juice. This compound presents antibacterial, anti-inflammatory, hypolipemic, and anticancer effects and is successfully used as a photosensitizing agent. The present review focuses on the research evidence related to the therapeutic properties of bergapten collected in recent years. Many preclinical and in vitro studies have been evidenced the therapeutic action of BP; however, few clinical trials have been carried out to evaluate its efficacy. These clinical trials with BP are mainly focused on patients suffering from skin disorders such as psoriasis or vitiligo. In these trials, the administration of BP (oral or topical) combined with UV irradiation induces relevant lesion clearance rates. In addition, beneficial effects of bergamot extract were also observed in patients with altered serum lipid profiles and in people with nonalcoholic fatty liver. On the contrary, there are no clinical trials that investigate the possible effects on cancer. Although the bioavailability of BP is lower than that of its 8-methoxypsoralen (8-MOP) isomer, it has fewer side effects allowing higher concentrations to be administered. In conclusion, although the use of BP has therapeutic applications on skin disorders as a sensitizing agent and as components of bergamot extract as hypolipemic therapy, more trials are necessary to define the doses and treatment guidelines and its usefulness against other pathologies such as cancer or bacterial infections.
SN 1942-0994
YR 2022
FD 2022-04-25
LK https://hdl.handle.net/20.500.13003/19747
UL https://hdl.handle.net/20.500.13003/19747
LA eng
NO Quetglas-Llabres MM, Quispe C, Herrera-Bravo J, Catarino MD, Pereira OR, Cardoso SM, et al. Pharmacological Properties of Bergapten: Mechanistic and Therapeutic Aspects. Oxid Med Cell Longev. 2022 Apr 25;2022:8615242.
DS Docusalut
RD 18 jun. 2026